Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMRN NASDAQ:ITRM NASDAQ:NEPH NASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMRNIMMURON$1.73-13.8%$5.04$1.50▼$2.87$10.94M0.8263,368 shs12,391 shsITRMIterum Therapeutics$0.92-6.5%$0.98$0.81▼$3.02$36.84M2.791.08 million shs1.77 million shsNEPHNephros$3.65+1.8%$3.37$1.36▼$5.00$38.65M1.0918,587 shs17,260 shsRANIRani Therapeutics$0.41-1.2%$0.57$0.39▼$3.85$25.85M-0.021.15 million shs930,843 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMRNIMMURON-2.13%+3.95%+6.11%+2.56%-30.04%ITRMIterum Therapeutics+1.03%-9.26%0.00%-9.26%-24.03%NEPHNephros+3.77%-4.53%-5.29%+82.75%+65.74%RANIRani Therapeutics+1.68%-36.86%-18.88%-64.37%-88.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMRNIMMURON1.491 of 5 stars3.53.00.00.01.10.00.0ITRMIterum Therapeutics2.0815 of 5 stars3.53.00.00.03.30.00.0NEPHNephros2.8037 of 5 stars3.55.00.00.02.70.80.0RANIRani Therapeutics2.3444 of 5 stars3.51.00.00.03.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMRNIMMURON 3.00Buy$5.00189.86% UpsideITRMIterum Therapeutics 3.00Buy$9.00882.53% UpsideNEPHNephros 3.00Buy$5.0037.14% UpsideRANIRani Therapeutics 3.00Buy$7.331,679.94% UpsideCurrent Analyst Ratings BreakdownLatest IMRN, RANI, NEPH, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025RANIRani TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.005/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMRNIMMURON$3.21M3.14N/AN/A$1.46 per share1.18ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/ANEPHNephros$14.16M2.73$0.02 per share172.41$0.81 per share4.50RANIRani Therapeutics$1.03M25.28N/AN/A$0.06 per share6.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMRNIMMURON-$4.55MN/A0.00N/AN/AN/AN/AN/AN/AITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)NEPHNephros$70K$0.0752.09∞N/A5.16%9.43%7.20%8/6/2025 (Estimated)RANIRani Therapeutics-$30.02M-$0.99N/AN/AN/AN/A-1,258.76%-80.52%8/5/2025 (Estimated)Latest IMRN, RANI, NEPH, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ITRMIterum Therapeutics-$0.13N/AN/AN/AN/AN/A8/5/2025Q2 2025RANIRani Therapeutics-$0.19N/AN/AN/AN/AN/A5/15/2025Q1 2025NEPHNephros-$0.0050$0.0526+$0.0576$0.05$3.67 million$4.88 million5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A5/13/2025Q1 2025RANIRani Therapeutics-$0.22-$0.22N/A-$0.22N/A$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMRNIMMURONN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMRNIMMURONN/A6.805.92ITRMIterum TherapeuticsN/A3.723.58NEPHNephrosN/A5.924.64RANIRani Therapeutics2.750.880.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMRNIMMURON0.12%ITRMIterum Therapeutics9.21%NEPHNephros41.10%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipIMRNIMMURON7.01%ITRMIterum Therapeutics9.20%NEPHNephros6.70%RANIRani Therapeutics45.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMRNIMMURONN/A5.85 million5.44 millionNot OptionableITRMIterum Therapeutics1040.00 million36.32 millionNot OptionableNEPHNephros3010.60 million9.89 millionNot OptionableRANIRani Therapeutics11063.21 million34.71 millionOptionableIMRN, RANI, NEPH, and ITRM HeadlinesRecent News About These CompaniesRani Therapeutics Shares Drop Sharply Following $3 Million Direct Offering AnnouncementJuly 15 at 5:03 PM | msn.comRani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct OfferingJuly 15 at 9:32 AM | globenewswire.comRani Therapeutics (NASDAQ:RANI) Shares Up 8.4% - Here's What HappenedJuly 15 at 4:21 AM | americanbankingnews.comRani Therapeutics Shares Surge After ENDO 2025 Presentation AnnouncementJuly 14, 2025 | msn.comRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating ...July 14, 2025 | bakersfield.comBRani Therapeutics to Present Preclinical Data on RaniPill® Capsule at ENDO 2025 ConferenceJuly 14, 2025 | quiverquant.comQRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous DeliveryJuly 14, 2025 | globenewswire.comGenelux Appoints Groen as General Counsel From Rani TherapeuticsJuly 8, 2025 | news.bloomberglaw.comNRani Therapeutics announces annual meeting resultsMay 30, 2025 | investing.comRani Therapeutics strikes deal to issue new warrantsMay 21, 2025 | uk.investing.comRANI: 1Q:25 Financial ResultsMay 20, 2025 | finance.yahoo.comRani Therapeutics Announces Research Agreement with ChugaiMay 19, 2025 | globenewswire.comRani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate UpdateMay 13, 2025 | globenewswire.comRani Therapeutics Faces Nasdaq Compliance ChallengeMay 6, 2025 | tipranks.comStifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)April 23, 2025 | markets.businessinsider.comRani Therapeutics management to meet virtually with Lake StreetApril 17, 2025 | markets.businessinsider.comRANI: 2024 Financial ResultsApril 3, 2025 | finance.yahoo.comEarnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024April 2, 2025 | investing.comQ4 2024 Rani Therapeutics Holdings Inc Earnings CallApril 1, 2025 | finance.yahoo.comRani Therapeutics reports Q4 EPS (27c), consensus (23c)April 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMRN, RANI, NEPH, and ITRM Company DescriptionsIMMURON NASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Iterum Therapeutics NASDAQ:ITRM$0.92 -0.06 (-6.43%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Nephros NASDAQ:NEPH$3.64 +0.07 (+1.82%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Rani Therapeutics NASDAQ:RANI$0.41 0.00 (-0.94%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.